Search
bezlotoxumab (Zinplava)
Indications:
- prevention of recurrence of Clostridium difficile infection [2,3]
Mechanism of action:
- binds C difficile toxin B
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
References
- Wikipedia: Bezlotoxumab
https://en.wikipedia.org/wiki/Bezlotoxumab
- Merk News Release. Oct 21, 2016
FDA Approves Merck's ZINPLAVA (bezlotoxumab) to Reduce
Recurrence of Clostridium difficile Infection (CDI) in Adult
Patients Receiving Antibacterial Drug Treatment for CDI Who
Are at High Risk of CDI Recurrence
http://www.mercknewsroom.com/news-release/corporate-news/fda-approves-mercks-zinplava-bezlotoxumab-reduce-recurrence-clostridium-
- Wilcox MH, Gerding DN, Poxton IR et al
Bezlotoxumab for Prevention of Recurrent Clostridium difficile
Infection.
N Engl J Med 2017; 376:305-317 January 26, 2017
PMID: 28121498
http://www.nejm.org/doi/full/10.1056/NEJMoa1602615
- Bartlett JG
Bezlotoxumab - A New Agent for Clostridium difficile Infection.
N Engl J Med 2017; 376:305-317 January 26, 2017
PMID: 28121509
http://www.nejm.org/doi/full/10.1056/NEJMe1614726